US Patent

US11654133 — Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy

Method of Use · Assigned to SK Biopharmaceuticals Co Ltd · Expires 2039-06-16 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a combination therapy using cenobamate and one or more antiepileptic drugs for preventing or treating neurological disorders like epilepsy.

USPTO Abstract

The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.

Drugs covered by this patent

Xcopri (CENOBAMATE) · Sk Life

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3610`	—	Xcopri
`U-3610`	—	Xcopri
`U-3610`	—	Xcopri
`U-3610`	—	Xcopri
`U-3610`	—	Xcopri
`U-3610`	—	Xcopri

Patent Metadata

Patent number: US11654133
Jurisdiction: US
Classification: Method of Use
Expires: 2039-06-16
Drug substance claim: No
Drug product claim: No
Assignee: SK Biopharmaceuticals Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.